Dr. Stephen Brannan, Chief Medical Officer, Karuna Therapeutics discusses the need for creating and delivering transformative medicines for people living with psychiatric and neurological conditions particularly schizophrenia. Pairing the muscarinic agonist with a pan-cholinergic antagonist that does not cross into the central nervous system, KarXT is mitigating the peripheral side effects like weight gain and sedation but still retaining the benefits from muscarinic agonist.
@KarunaPharma $KRTX #NeuroTwitter #CNS #schizophrenia #schizoprenia #Neuroscience
KarunaTX.com
Download the transcript here
Empowered Patient Podcast